IDYA Stock Cash Flow Statements

IDEAYA Biosciences Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

IDEAYA Biosciences Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30

cash flows from operating activities
net income	-77,491,000	-72,178,000	-130,312,000	-51,821,000	-52,772,000	-39,572,000	-33,955,000	-27,440,000	-27,926,000	-23,640,000	-24,201,000	1,615,000	-22,056,000	-14,013,000	-18,212,000	-11,582,000	-10,947,000	-9,021,000	-5,135,000	-4,926,000	-12,391,000	-12,043,000	-10,781,000	-10,969,000
adjustments to reconcile net income to net cash from operating activities
depreciation and amortization	718,000	600,000	572,000	577,000	622,000	616,000	629,000	640,000	619,000	588,000	558,000	569,000	510,000	464,000	448,000	451,000	444,000	382,000	361,000	347,000	337,000	336,000	330,000	324,000
net accretion of discounts on marketable securities	-2,692,000	-3,778,000
stock-based compensation	11,868,000	10,237,000	9,485,000	9,215,000	9,734,000	6,312,000	4,798,000	5,301,000	4,731,000	3,659,000	2,975,000	3,005,000	3,044,000	2,605,000	2,064,000	2,197,000	2,058,000	1,918,000	1,046,000	981,000	824,000	758,000	719,000	518,000
amortization of right-of-use assets	515,000	533,000		435,000	475,000	466,000		386,000	379,000	372,000		356,000
changes in assets and liabilities
prepaid expenses and other assets	-500,000	-1,970,000	-1,736,000	-934,000	-371,000	-3,133,000	-724,000	1,187,000	-3,881,000	1,373,000	-1,627,000	-441,000	-451,000	400,000	206,000	1,324,000	-1,918,000	199,000	-429,000	767,000	-1,945,000	1,097,000	108,000	-328,000
accounts payable	-364,000	2,728,000	2,976,000	-3,939,000	9,696,000	-453,000	1,745,000	-699,000	1,601,000	-12,000	397,000	-449,000	1,053,000	863,000	-7,000	377,000	536,000	260,000	-459,000	493,000	227,000	-36,000	-42,000	36,000
accrued and other liabilities	4,843,000	2,875,000	2,274,000	2,895,000	6,898,000	-1,273,000	2,481,000	2,414,000	-2,841,000	-419,000	323,000	1,150,000	2,959,000	140,000	476,000	2,012,000	2,339,000	-615,000	1,806,000	1,437,000	-635,000	384,000	1,030,000	55,000
lease liabilities	629,000	611,000	-86,000	-280,000	-538,000	-465,000	-487,000	-475,000	-459,000	-451,000	-442,000	-431,000	-417,000	-409,000	-401,000	-392,000	-377,000	-372,000	-363,000	870,000	-281,000	-275,000	-270,000	-402,000
net cash from operating activities	-62,474,000	-60,342,000	-121,655,000	-49,234,000	-32,882,000	-43,813,000	-23,748,000	-30,174,000	-33,460,000	-27,842,000	-23,370,000	-24,166,000	-19,992,000	-19,647,000	-16,657,000	-12,468,000	-12,930,000	-13,724,000	-11,596,000	90,210,000	-13,606,000	-9,545,000	-8,706,000	-10,550,000
capex	-660,000	-676,000	-901,000	776,000	-1,111,000	-1,142,000	-838,000	-603,000	-1,030,000	703,000	0	-1,101,000	-1,470,000	149,000	-699,000	-650,000	-583,000	-620,000	180,000	-337,000	220,000	33,000	-216,000	-113,000
free cash flows	-63,134,000	-61,018,000	-122,556,000	-48,458,000	-33,993,000	-44,955,000	-24,586,000	-30,777,000	-34,490,000	-27,139,000	-23,370,000	-25,267,000	-21,462,000	-19,498,000	-17,356,000	-13,118,000	-13,513,000	-14,344,000	-11,416,000	89,873,000	-13,386,000	-9,512,000	-8,922,000	-10,663,000
cash flows from investing activities
purchases of property and equipment	-663,000	-1,330,000	-1,102,000	-457,000	-973,000	-1,325,000	-838,000	-603,000	-884,000	-43,000	0	-1,101,000	-1,941,000	-401,000	-605,000	-458,000	-578,000	-1,003,000	-179,000	-245,000			-216,000	-82,000
purchases of marketable securities	-127,553,000	-105,207,000	-337,041,000	-213,724,000	-164,763,000	-475,781,000	-221,605,000	-81,832,000	-220,247,000	-72,296,000	-65,501,000	-88,085,000	-37,922,000	-64,300,000	-32,568,000	-149,382,000	-94,308,000	-38,738,000	-27,902,000	-188,166,000	-14,993,000	-11,253,000	-1,887,000	-47,659,000
maturities of marketable securities	174,134,000	186,354,000	141,034,000	194,145,000	234,293,000	123,135,000	110,500,000	133,782,000	99,750,000	95,860,000	55,225,000	70,503,000	53,179,000	46,940,000	32,760,000	93,533,000	41,487,000	76,176,000	23,527,000	4,828,000	46,050,000	22,159,000	5,990,000	49,444,000
net cash from investing activities	45,918,000	79,817,000	-197,109,000	-20,036,000	68,557,000	-353,971,000	-111,943,000	51,347,000	-121,381,000	23,521,000	-10,276,000	-18,683,000	13,316,000	-17,761,000	-413,000	-56,307,000	-49,381,000	36,435,000	-4,554,000	-183,583,000	30,988,000	10,906,000	3,887,000	-38,441,000
cash flows from financing activities
proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs	-25,000	25,009,000	-65,000	-27,000	36,321,000	343,650,000	-156,000	26,228,000	-34,000	2,560,000	-138,000	9,070,000	-66,000	-9,000	-23,000	-22,000	15,416,000	41,892,000
proceeds from espp purchase				0				0				-349,000				0				0
proceeds from exercise of common stock options	410,000	1,134,000	2,500,000	2,441,000	2,081,000	5,461,000		1,855,000														34,000	38,000	184,000
net cash from financing activities	1,205,000	26,143,000	2,753,000	286,504,000	39,183,000	349,111,000	140,894,000	27,834,000	191,063,000	2,926,000	324,000	95,697,000	491,000	653,000	688,000	86,776,000	15,986,000	42,004,000	6,949,000	27,068,000	94,699,000	34,000	38,000	-276,000
net increase in cash, cash equivalents and restricted cash	-15,351,000	45,618,000	-316,011,000	217,234,000			5,203,000	49,007,000			-33,322,000	52,848,000			-16,382,000	18,001,000	-46,325,000	64,715,000	-9,201,000	-66,305,000	112,081,000	1,395,000	-4,781,000	-49,267,000
cash, cash equivalents and restricted cash	-15,351,000	130,801,000	-316,011,000	217,234,000	74,858,000	109,102,000	5,203,000	49,007,000	36,222,000	67,343,000	-33,322,000	52,848,000	-6,185,000	55,397,000	-16,382,000	18,001,000	-46,325,000	136,858,000	-9,201,000	-66,305,000	112,081,000	35,568,000	-4,781,000	-49,267,000
cash, cash equivalents and restricted cash, at beginning of period	0	85,183,000	0	0	0	157,775,000	0	0	0	68,738,000	0	0	0	92,152,000	0	0	0	72,143,000	0	0	0	34,173,000	0	0
cash, cash equivalents and restricted cash, at end of period	-15,351,000	130,801,000	-316,011,000	217,234,000	74,858,000	109,102,000	5,203,000	49,007,000	36,222,000	67,343,000	-33,322,000	52,848,000	-6,185,000	55,397,000	-16,382,000	18,001,000	-46,325,000	136,858,000	-9,201,000	-66,305,000	112,081,000	35,568,000	-4,781,000	-49,267,000
reconciliation of cash, cash equivalents and restricted cash
cash and cash equivalents	-15,351,000	129,996,000	-315,905,000	217,234,000	74,704,000	108,345,000	5,168,000	49,007,000	35,606,000	67,237,000	-33,322,000	52,848,000	-6,185,000	55,291,000	-16,382,000	18,001,000	-46,325,000	136,752,000	-9,201,000	-66,305,000	112,081,000	35,462,000	-4,781,000	-49,267,000
restricted cash	0	805,000	-106,000	0	154,000	757,000	35,000	0	616,000	106,000	0	0	0	106,000	0	0	0	106,000	0	0	0	106,000	0	0
supplemental disclosure of cash flow information:
cash paid for interest			0	3,000	10,000	12,000	32,000	11,000	13,000	13,000	14,000	14,000	16,000	16,000	16,000	18,000	18,000	19,000	20,000	20,000	21,000	21,000	22,000	45,000
supplemental non-cash investing and financing activities:
right-of-use asset obtained in exchange for a new operating lease liability	0	6,186,000	461,000
purchases of property and equipment in accounts payable and accrued liabilities	3,000	654,000	201,000	1,233,000	-138,000	183,000			-146,000	746,000			471,000	550,000	-94,000	-192,000	-5,000	383,000	359,000	-92,000	220,000	33,000		-31,000
unpaid at-the-market offering program costs			-3,000	0
net amortization (accretion) of premiums (discounts) on marketable securities			-4,916,000	-5,363,000	-6,640,000	-6,314,000	-3,876,000	-3,566,000	-2,554,000	-1,557,000	-1,127,000	-86,000	169,000	349,000	469,000	466,000	445,000	454,000
amortization of right of use assets
accounts receivable			17,000	-19,000	14,000	3,000	6,685,000	-6,543,000	308,000	-257,000	3,238,000	-3,161,000	409,000	406,000	-85,000	307,000	1,597,000	-1,045,000
contract liabilities							-1,439,000	-1,379,000	-3,437,000	-7,498,000	-3,828,000	-26,293,000	-5,562,000	-10,796,000	-1,951,000	-7,957,000	-7,431,000	-6,202,000	-7,260,000
proceeds from issuance of common stock in public offering, net of issuance costs
proceeds from issuances of pre-funded warrants
proceeds from espp purchases
unpaid offering costs							8,000	-316,000	295,000	56,000	-457,000						111,000	60,000
proceeds from issuance of common stock upon public offering, net of issuance costs								-249,000												6,789,000
proceeds from issuance of pre-funded warrants to purchase common stock, net of issuance costs								0
net decrease in cash, cash equivalents and restricted cash						-48,673,000				-1,395,000
accrued atm costs						145,000
sales of marketable securities															0	0							0	-40,144,000
proceeds from exercise of common stock options, net of repurchases										366,000	517,000	496,000	-227,000	662,000	341,000	808,000	243,000	112,000	173,000	291,000
cash paid for income taxes															0	0			0	0	0	1,000	0	0
vesting of early exercised options and restricted stock															1,000	2,000	3,000	18,000	12,000	13,000	15,000	16,000	26,000	17,000
loss on sale of property and equipment																				0	0	2,000
realized gain on marketable securities																				0
right-of-use assets														344,000	336,000	329,000	324,000	318,000	311,000	-921,000	233,000	229,000	223,000	266,000
proceeds from issuance of common stock in private placement, net of issuance costs																			0
right-of-use asset obtained in exchange for new operating lease liability
net incresae (decrease) in cash, cash equivalents and restricted cash														-36,755,000
conversion of redeemable convertible preferred stock into common stock																							0	0
issuance of series b redeemable convertible preferred stock pursuant to license agreement
change in fair value of redeemable convertible preferred stock liability
landlord contributions for leasehold improvements
gain on sale of property and equipment																							0	11,000
gain on sale of marketable securities
deferred rent
proceeds from issuance of redeemable convertible preferred stock, net of issuance costs
payments of deferred offering costs
unpaid deferred offering costs
extinguishment of redeemable convertible preferred stock liability
net amortization of premiums and discounts on marketable securities																				129,000	26,000	5,000		-61,000
gain on sales of marketable securities																						-2,000		0
proceeds from issuance of common stock in initial public offering, net of issuance costs																							0
leasehold improvements acquired through tenant improvement allowance
proceeds from issuance of initial public offering, net of issuance costs

We provide you with 20 years of cash flow statements for IDEAYA Biosciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of IDEAYA Biosciences stock. Explore the full financial landscape of IDEAYA Biosciences stock with our expertly curated income statements.

The information provided in this report about IDEAYA Biosciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.